- 1 Genetic analysis of cognitive preservation in the midwestern
- 2 Amish reveals a novel locus on chromosome 2.
- 4 Author names and affiliations: Leighanne R Main\* a,b,c,
- 5 Yeunjoo E Song b,c, Audrey Lynn b,c, Renee A Laux b, Kristy
- 6 L Miskimen b, Michael D Osterman b, Michael L Cuccaro d,e,
- 7 Paula K Ogrocki f,g, Alan J Lerner f,g, Jeffery M Vance d,e, M
- 8 Denise Fuzzell b, Sarada L Fuzzell b, Sherri D Hochstetler b,
- 9 Daniel A Dorfsman de, Laura J Caywood d, Michael B
- Prough <sub>d</sub>, Larry D Adams <sub>d</sub>, Jason E Clouse <sub>d</sub>, Sharlene D
- 11 Herington d, William K Scott d,e, Margaret A Pericak-Vance
- 12 d,e, Jonathan L Haines\* a,b,c
- <sub>a</sub> Departments of Genetics and Genome Sciences, Case
- 15 Western Reserve University, 10900 Euclid Ave, Cleveland,
- 16 OH, USA, 44106

3

13

- b Department of Population and Quantitative Health
- 18 Sciences, Case Western Reserve University School of
- Medicine, 10900 Euclid Ave, Cleveland, OH, USA, 44016
- <sub>c</sub> Cleveland Institute of Computational Biology, Case
- 21 Western Reserve University School of Medicine, 10900
- Euclid Ave, Cleveland, OH, USA, 44106

- 23 d John P Hussman Institute for Human Genomics, University
- of Miami Miller School of Medicine, 1501 NW 10th Ave,
- 25 Miami, FL, USA, 33136
- <sub>e</sub> Dr. John T Macdonald Foundation Department of Human
- 27 Genetics, University of Miami Miller School of Medicine,
- 28 1501 NW 10th Ave, Miami, FL, USA, 33136
- 29 f Department of Neurology, University Hospitals Cleveland
- Medical Center, 11100 Euclid Ave, Cleveland, OH, USA,
- 31 44106

35

- 32 g Department of Neurology, Case Western Reserve
- University School of Medicine, 10900 Euclid Ave, Cleveland,
- 34 OH, USA, 44106
- \*Corresponding Authors: Leighanne R Main
- 37 (Irm91@case.edu), and Jonathan L Haines
- 38 (jlh213@case.edu)

ABSTRACT

39

40 INTRODUCTION: Alzheimer disease (AD) remains a debilitating condition with limited treatments and additional 41 42 therapeutic targets needed. Identifying AD protective genetic 43 loci may identify new targets and accelerate identification of 44 therapeutic treatments. We examined a founder population 45 to identify loci associated with cognitive preservation into 46 advanced age. 47 METHODS: Genome-wide association and linkage analyses 48 were performed on 946 examined and sampled Amish 49 individuals, aged 76-95, who were either cognitively 50 unimpaired (CU) or impaired (CI). 51 RESULTS: 12 SNPs demonstrated suggestive association 52 (P≤5x10<sup>-4</sup>) with cognitive preservation. Genetic linkage 53 analyses identified >100 significant (LOD≥3.3) SNPs, some 54 which overlapped with the association results. Only one 55 locus on chromosome 2 retained significance across multiple 56 analyses. 57 DISCUSSION: A novel significant result for cognitive 58 preservation on chromosome 2 includes the genes *LRRTM4* 59 and CTNNA2. Additionally, the lead SNP, rs1402906, 60 impacts the POU3F2 transcription factor binding affinity, 61 which regulates *LRRTM4* and *CTNNA2*.

ABBREVIATIONS

62

74

- 63 AD Alzheimer Disease
- 64 AGDB Anabaptist Genealogical Database
- 65 CI Cognitively impaired
- 66 CU Cognitively unimpaired
- 67 GWAS Genome-wide association study
- 68 HLOD Heterogeneity logarithm of the odds
- 69 LD Linkage disequilibrium
- 70 LOD Logarithm of the odds
- 71 MCI Mild cognitive impairment
- 72 MCMC Markov chain Monte Carlo
- 73 QC Quality control

## 75 1 BACKGROUND

- Dementia, defined broadly as a decline or loss in memory
- and other cognitive abilities, is an overarching term that
- 78 incorporates many underlying conditions. Alzheimer disease
- 79 (AD), the most common form of dementia ( $\sim$ 60-80% of
- cases), affects more than five million people in the U.S. and
- is becoming more prevalent as the world population ages.[1]
- To date there have been over 70 genetic loci associated with
- increased risk for AD-associated dementia, [2–4] some of
- which have been targets for therapeutic development.
- 85 However, no existing treatments or therapies addressing AD
- and other dementias have been sufficient to significantly

87 ameliorate AD pathology or delay onset and decline.[5] An 88 alternative and less often used approach for generating 89 therapeutic targets is the identification of genetic variation 90 that associates with a *decreased* risk for AD-associated 91 dementia (e.g., protective loci). Focusing on protective loci is 92 a strategy demonstrating higher success rates than focusing 93 on loci with increased risk when translated into 94 therapeutics.[6] 95 96 Phenotypically, protective AD genetic loci result in 97 maintenance of cognitive abilities (e.g., cognitive 98 preservation). To identify loci promoting cognitive 99 preservation, we analyzed members of the Ohio and Indiana 100 Amish, a founder population of European ancestry. For our 101 analyses, we identified older individuals who were 102 cognitively unimpaired (CU) but at high risk for developing 103 AD, defined as having a first-degree relative with dementia. 104 Analyses included cognitively impaired (CI) individuals as 105 controls. The relatively uniform lifestyle of the midwestern 106 Amish reduces the variability of environmental influences on 107 many phenotypes, while their endogamous cultural norms 108 increase the frequency of some normally rare genomic 109 variants.[7,8] Both genetic association analyses and family-

based linkage analyses were used to identify loci associated with cognitive preservation.

## 2 METHODS

110

111

112

2.1 Data Collection and Cognitive Screening 113 114 The analyzed dataset consisted of Amish individuals from 115 Ohio and Indiana who were 76-95 years old at their last 116 exam. Individuals underwent a panel of neurocognitive 117 assessments to evaluate their cognitive status. Assessments 118 included the Consortium to Establish a Registry for 119 Alzheimer's Disease (CERAD) neuropsychological 120 assessment[9], the Modified Mini-Mental State (3MS) 121 exam[10], the AD8 Dementia Screening Interview[11], and 122 the Trail Making Test for Dementia Studies.[12] Cognitive 123 data from 2,096 individuals were available for analysis. 124 Individuals were classified as cognitively impaired (CI) based 125 on established testing thresholds, with determinations 126 confirmed by a clinical adjudication board. Categories 127 defined by the adjudication board included cognitively 128 unimpaired for age-normed benchmarks (CU), mild cognitive 129 impairment (MCI), borderline impairment, or cognitively 130 impaired (CI). Additional personal and medical information 131 was assessed to provide context for other factors related to 132 cognition scores, such as self-reported depression.

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

Individuals unable to be categorized as CI or CU were excluded from genetic analyses. All participants provided written informed consent for participation in this study. 2.2 Genotyping Blood was collected from participants for DNA extraction. All samples were genotyped via the Multi-Ethnic Genotyping Array (MEGA<sup>ex</sup>) or Global Screening Array (GSA) genotyping chips. The MEGA<sup>ex</sup> chip recognized over 2 million loci, and the GSA chip recognized 660,000 loci. Custom markers were also included on the MEGA<sup>ex</sup> chip (6,000 SNPs), including disease-associated loci previously identified in Amish and European populations.[13,14] 2.3 Genotype Quality Control Initial quality control (QC) was done as previously described.[15] 256,978 SNPs passed QC across both chips. After additional pruning for linkage disequilibrium (LD), 167,196 SNPs were used to inform the number of effective independent tests done in the association analyses. Genotyped individuals were filtered for sex discrepancies and low call rates (<96%). Familial relationships were

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

verified across samples. Age was defined as follows for all analyses: for CU individuals, age at the last study visit; for CI individuals, age at CI diagnosis. Participants whose age or familial relationships were missing were not included in the current analyses. Additional samples were dropped due to being under 75 years of age (n = 748) or a diagnosis other than CI/CU (n = 343). After QC, 946 individuals were available for analysis (66% CU; 59% female, Supplementary Table 1). Mean age for both CU and CI individuals was 82 years (Supplementary Figure 1). 2.4 Amish Genealogy To evaluate familial relationships in this dataset, we consulted the Anabaptist Genealogical Database (AGDB).[16] All individuals were connected into a single, large, 14-generation pedigree (n=8,222) generated using pedigraph[17] (Figure 1A). These relationships were used to correct for relatedness in our genetic analyses. To conduct chromosome-wide genetic linkage analyses smaller pedigrees were required, so PedCut[18] was used to create sub-pedigrees with at least two cognitively preserved individuals in each (see Figure 1B for an example). The 14generation pedigree was split based on pedigree size, or bit-

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

size. Bit sizes evaluated were 21 (n = 103 sub-pedigrees) and 22 (n = 98) for linkage analysis on the autosomes. An additional 23-bit (n = 94) pedigree size was used for linkage analysis on the X chromosome. 2.5 Principal Component Analysis and Association Analysis Principal Component Analysis (PCA) was performed via Principal Component Analysis in Related Samples (PC-AiR), part of the GENetic Estimation and Inference in Structured samples (GENESIS) R package.[19] PC-AiR adjusted for cryptic relatedness to generate principal components (PCs) based on the overall population structure, not just family structure. PC-AiR created kinship estimates for each individual based on the pedigree relationship information obtained from the 14-generation pedigree (Figure 1A). Model-free estimation of recent genetic relatedness (PC-Relate)[20] then used the PCs generated from PC-AiR to adjust for the population substructure and ancestry to provide an accurate estimate of recent genetic relatedness due to family structure, correcting for the extensive and complex relatedness in this dataset by generating a Genetic Relationship Matrix (GRM). GENESIS software was then

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

used for association analysis.[19] Association analysis was completed using covariates of age, sex, and the GRM, adjusting for the first two PCs. To accommodate the LD structure specific to the Amish, we used the simpleM method[21–23] to define appropriate significance thresholds for the study population. SimpleM uses PCA and linkage disequilibrium (LD) between SNPs to help estimate the effective number of independent tests for the dataset. This method generated a significance threshold of  $6.4 \times 10^{-7}$ . The X chromosome was also investigated for association. 9,852 X-linked SNPs were available after QC. XWAS[24] was used to perform sex-stratified association testing. Two tests were performed, one treating males as heterozygous for SNPs on the X chromosome, and the other treating males as homozygous for SNPs on the X chromosome, both yielded to the same results. Age and the first five PCs were included as covariates.

2.6 Linkage Analysis 223 224 Due to computational complexity, the 14-generation 8,222-225 person Amish pedigree (Figure 1A) was divided into smaller 226 sub-pedigrees (e.g., Figure 1B) to perform both 227 nonparametric (NPL) and parametric linkage analysis. A total 228 of 295 sub-pedigrees were used in linkage analyses 229 (Supplementary Table 2). 230 231 Model-based (parametric) and model-free (nonparametric or 232 NPL) linkage analyses were performed using MERLIN.[25] To test for linkage, the null hypothesis of no linkage was 233 234 compared to the likelihood of linkage  $(0 \le \square_1 < 0.5)$  between 235 the phenotype and SNP within each sub-pedigree. A 236 logarithm of the odds (LOD) score was calculated within 237 each sub-pedigree and then summed across sub-pedigrees. 238 In addition, the proportion of sub-pedigrees linked to a 239 particular SNP (α) was calculated as part of a heterogeneity 240 LOD score (HLOD). 241 242 For parametric two-point and multipoint linkage tests, both dominant and recessive models were tested on sub-243 244 pedigrees. These pedigrees each contained at least three 245 but up to 11 CU individuals, with varying numbers of CI

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

individuals ranging from zero to two. For tests modeling a dominant inheritance model, a trait allele frequency (AF) of 0.001 was used with penetrances of 0.0001, 1.0, and 1.0 for zero, one, and two copies of the trait allele, respectively. For the recessive model, the trait AF was 0.05 with penetrance of 0.0001, 0.0001, and 1.0 for zero, one, and two copies of the trait allele, respectively. In nonparametric linkage (NPL) and parametric analyses, both two-point and multipoint linkage was examined. Twopoint NPL and parametric analyses were performed on the full set of post-QC SNPs (n = 256,978), while multipoint NPL and parametric analyses were carried out on two different sets of pruned SNPs to minimize the impact of linkage disequilibrium (LD). An r<sup>2</sup> threshold of 0.16 was used to define a set of 85,857 pruned SNPs for the multipoint analyses.[26] MERLIN's NPL<sub>all</sub> function was utilized for NPL analyses to construct a linear model of linkage. LOD and HLOD scores surpassing the defined thresholds for suggestive ( $\geq 1.86$ ) and significant linkage ( $\geq 3.3$ )[27] were examined in more depth.

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

MINX software[25], an extension of MERLIN, was used for X chromosome linkage analysis. For two-point NPL and parametric analyses, a set of 9,852 X chromosome SNPs was used, and for multipoint NPL and parametric analyses, a pruned set of 153 SNPs with an  $r^2 < 0.02$  and MAF  $\ge 0.40$ was used. Multipoint NPL analysis utilized a sex-averaged genetic map[28], and model penetrances, adjusted for males and females, were the same as defined for the autosomal linkage analyses above. For the subset of the loci where HLOD scores surpassed the significance threshold, 21- and 22-bit pedigrees driving the positive HLOD scores were examined for more distant connections allowing for the construction of larger pedigrees. 21- or 22-bit sub-pedigrees were merged when either identical AGBD IDs or first-degree relative AGBD IDs appeared (see Figure 1C for a larger pedigree example constructed for chromosome 2-linked sub-pedigrees). Six loci, one on each of chromosomes 1, 2, 3, 7, 11 and 17 met significance criteria, and larger pedigrees were possible for five of these loci, the exception being the chromosome 3 locus. MORGAN[29,30] was used to calculate regionspecific LOD scores for these larger, more complex

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

pedigrees using both dominant and recessive models. Any linkage originally appearing under dominant inheritance patterns was verified by MCMC analysis also utilizing dominant parameters, recessive results were treated similarly. MORGAN allowed for larger pedigrees and provided an alternative linkage method, Markov chain Monte Carlo (MCMC), to investigate the same loci. The trait allele frequency for CU was coded as very rare (CU = 0.0001) for all analyses, similar to, but slightly more restrictive than previous models run with MERLIN, in order to specify a single founder for each allele. Additionally, MCMC penetrance models utilized the same penetrances specified in MERLIN analyses. MCMC was performed with a maximum of 8 SNPs, spaced at 1-5 cM intervals. The genetic maps generated by Halldorsson et al., 2019 were used.[31] D' and r<sup>2</sup> values were generated specifically for our Amish population to verify that the resulting LOD scores were not influenced by LD.

311

3 RESULTS 312 3.1 Genome-Wide Association Analysis for 313 Cognitive Preservation 314 315 No SNPs reached the genome-wide significance threshold 316 defined by simpleM for this population, but eleven loci 317 (chromosomes 1, 3, 5, 6, 7, 11, 13, 14, 15, 16) surpassed the suggestive threshold (p  $\leq$  10<sup>-4</sup>) (Supplementary Table 3 318 319 and Figure 2). Genomic inflation was 0.98 after the GRM, 320 age, and sex covariates were applied to the model 321 (Supplementary Figure 2A). 322 323 No SNPs on the X chromosome were significant or 324 suggestive under either sex-stratified model (Figure 2). The 325 genomic inflation value was 0.98 for the X chromosome 326 (Supplementary Figure 2B). 327 3.2 Linkage Analyses for Cognitive Preservation 328 329 Pedigrees were grouped via bit-size, chosen based on 330 computational tractability for our analyses. For NPL 331 analyses, families of bit size 21 and 22 were examined (n = 332 201). In the two-point NPL analyses, 17 loci on 13

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

chromosomes surpassed the threshold for suggestive linkage (≥ 1.86) (Supplementary Figure 3A). Multipoint NPL analyses resulted in 10 suggestive loci on 10 different chromosomes (Supplementary Figure 3B). No SNPs reached statistical significance in any NPL analysis. Two-point dominant linkage analyses generated 72 significant (≥ 3.3) HLOD results spread across most chromosomes for both the 21- and 22-bit pedigrees (Figure 3 and Supplementary Figure 4A). In multipoint analyses, only chromosomes 12 and 17 had significant results for the dominant model (Supplementary Figure 4B). Two-point recessive linkage analyses generated significant results on 11 different chromosomes (Supplementary Figure 4C). No loci reached significance with a multipoint recessive model (Supplementary Figure 4D). Two-point parametric linkage analysis on the X chromosome led to 14 loci surpassing the threshold for suggestive linkage, but no loci were significant. No SNPs were seen as suggestive or significant in multipoint analyses on the X chromosome. See Supplemental Tables 3 and 4 for a full list of significant and suggestive loci, respectively, from linkage analyses.

3.3 Assessment of Significant and Suggestive 356 Genomic Regions 357 358 The need to use sub-pedigrees for linkage analysis 359 introduced an unknown amount of variability into the linkage 360 analysis calculations.[32] To address this issue, we 361 implemented an approach to filter the large number of loci 362 surpassing thresholds for suggestive or significant results in 363 GWAS and/or linkage. Some differences were seen across 364 the various bit size pedigrees, therefore, significant HLOD 365 scores in multiple linkage analyses in the same region were 366 a requirement for the locus to undergo further investigation. 367 Regions selected for follow-up were required to have 1) two 368 significant HLOD scores (≥3.3) in any two linkage analyses 369 and a significant or suggestive LOD score (≥1.86) in at least 370 one other linkage analysis; or 2) one suggestive result in the 371 GWAS (within 5 Mb), a significant HLOD score in any 372 linkage analysis, and a suggestive HLOD score in any other 373 linkage analysis. After applying these criteria, 6 regions of 374 interest were identified for further investigation, located on 375 chromosomes 1, 2, 3, 7, 11, and 17 (Table 1). When probing 376 within a 10 Mb region around each of these loci, we 377 observed two known AD-related genes (adsp.niagads.org), 378 *PICALM* (chromosome 11) and *EPHA1* (chromosome 7).

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

It is made available under a CC-BY-NC-ND 4.0 International license .

By examining which sub-pedigrees displayed the highest chromosome-specific LOD scores across multiple analyses, it was noted that some of these sub-pedigrees could be connected either by a specific individual or through a first degree relative. These related sub-pedigrees were combined into larger family pedigrees for five of the loci (chromosomes 1, 2, 7, 11, and 17), but were unable to be merged for the chromosome 3 locus. These five larger pedigrees were then used for the MCMC linkage analyses. Only the chromosome 2 locus, centered around SNP rs1402906, remained significant (HLOD = 4.87) after connection of the sub-pedigrees. MCMC analyses with identical parameters were performed to further verify these results, this time adding additional SNPs upstream and downstream of rs1402906 to widen the genomic window considering potential linkage. These additional analyses each considered 5 SNPs, and again rs1402906 retained the highest significance with a dominant model (LOD=4.14) (see Table 2 and Figure 4). The rs1402906 T allele frequency is 12% in the Amish, compared to 19% in the ALFA European population (dbSNP).[33] Of the 24 CU individuals who had

402 genotype data available, the genotype counts for rs1402906 403 were 7 TT, 12 CT, and 3 CC (Supplementary Table 6). 404 These CU individuals in the chromosome 2-linked pedigree 405 were all under 88 years of age. There were two CI 406 individuals in the chromosome 2-linked pedigree, both 407 displayed the CC genotype at rs1402906 and were >89 408 years. Despite the co-segregation of the T allele with most 409 CU individuals in this pedigree, the genotype frequencies are 410 essentially the same between CU and CI individuals in the 411 entire Amish population in the study (Supplementary Table 412 6). 413 3.4 Chromosome 2p *in Silico* Annotation 414 415 The UCSC genome browser was used to identify protein 416 coding genes on chromosome 2p11.2-13.1 spanning 10 cM 417 around the peak LOD score at rs1402906.[34] The protein 418 coding genes in this region include *REG1A*, *REG1B*, 419 CTNNA2, and LRRTM1 and LRRTM4 (Figure 5). In 420 addition, the Open Targets Platform eQTL and PheWAS 421 databases specified an eQTL associated with decreased 422 CTNNA2 expression with the "T" allele at rs1402906, as well 423 as an increased incidence within a study population of 424 individuals with autism.[35,36] The PheWAS database also

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

indicated a miniscule, but still significant, diminishment within a study population of Bipolar individuals. Sequences around the SNP demonstrating the peak LOD score, rs1402906, were investigated for potential promoter regions in the Eukaryotic Promoter Database (EPD)[37], as well as analyzed through PROMO, a transcription factor binding site (TFBS) identification tool developed by ALGGEN.[38,39] Cap Analysis of Gene Expression (CAGE) reads from the FANTOM5 project were also examined to investigate transcription start sites (TSS).[40] Although the 2p11.2-13.1 genomic region is relatively devoid of known genes, examination of transcription factor binding sites in this region via ALGGEN shows the transcription factor POU3F2 as having a perfect binding site consensus beginning 4bp upstream of rs1402906 when the genomic sequence contained the T allele at rs1402906.[41] Substitution of the alternative allele C nearly abolished the binding potential for POU3F2, with a low predicted binding score due to two base-pair mismatches in the recognition sequence. Another transcription factor, POU1F1a, demonstrates a perfect binding consensus 10bp upstream of

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

rs1402906. However, the alleles at rs1402906 do not disrupt the binding. Utilizing the EPD as well as CAGE reads uncovered HK3me1, HK3me3, and H3K27ac sites within 10bp of rs1402906, indicating a potential TSS as well as predicted enhancer activity.[42,43] 4 DISCUSSION Identifying protective genetic loci as a strategy for finding potential therapeutic targets is a methodology that yields higher success rates for clinical trials than other approaches.[6] For dementia, protective loci are associated with an outcome of cognitive preservation, which can result from either cognitive resilience or resistance. Cognitive resilience is observed when patients display typical dementia pathology, specifically a buildup of amyloid plagues and tangles in the brain in AD, without demonstrating any cognitive impairment or other dementia symptoms.[44] Cognitive resistance is defined by a lack of dementiaassociated symptoms without presenting dementia pathologies.[44] As the Amish undergo only pre-mortem diagnosis, their classification falls under cognitive preservation, which is either cognitive resilient or resistant. Previous studies for AD have identified multiple genes that

471 possess alleles that appear to confer some protection 472 against developing AD including, APP[45], APOE □2[46], 473 PLCG2[47], MS4A[48], ABCA1[49], RAB10[50], SORL1[51], 474 PICALM[52], EPHA1[4], and CASS4[4]. Although our ad hoc 475 filtering suggested possible effects near *PICALM* and 476 EPHA1, no SNPs in either gene demonstrated a protective 477 effect. 478 479 GWAS and linkage analyses identified 106 suggestive or 480 significant loci for cognitive preservation in the Amish 481 (Supplemental Table 3). To limit false positives, we focused only on areas yielding suggestive or significant associations 482 483 in multiple analyses. This limited our results to six areas of 484 interest across chromosomes 1, 2, 3, 7, 11, and 17 (Table 1 485 and Table 2). Notably, an effect of  $APOE \square 2$  was not 486 detected in any analysis, however this is likely because of 487 APOE □ 3's high allele frequency within the Amish and its 488 neutral phenotypic outcome, thereby preventing its 489 enrichment in either the case or control groups. APOE  $\Box$  2 490 was infrequent in this Amish population, with an allele 491 frequency of just 4.2%, compared to 19.5% in non-Hispanic 492 white populations, [53] making it likely too rare for analyses to 493 detect. A region on chromosome 2p11.2-13.1, centered

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

around rs1402906, demonstrated statistical significance consistently across multiple linkage analyses. By connecting several of the sub-pedigrees, we confirmed the transmission, providing additional evidence of linkage. Because significant allelic association or genetic linkage results do not necessarily identify causal variations, a 10 Mb region around the chromosome 2 locus peak was evaluated to develop a broader assessment of possible functional elements. While this region was not accompanied by association in the GWAS, PROMO predicted a POU3F2 TFBS with perfect consensus beginning 4bp upstream of rs1402906 when the genomic sequence contained the T allele. Though there remained a possibility of binding in the presence of the C allele at that site, consensus was markedly diminished as any potential binding would require only partial adherence to the site, with two of the seven base pairs in the binding locus being mismatched.[41] A majority (87%) of the individuals demonstrating cognitive preservation in the chromosome 2-linked pedigree (Figure 1C and Figure 4) have this T allele. Of the three CCgenotyped CU individuals, two married into the pedigree (i.e., were not otherwise closely related to the other pedigree

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

members), with the third CC genotyped individual (age 80) being below the average age of onset for CI in the Amish population (age 82) and a child of one of the married-ins. Additionally, the average age of onset for CI was 89.5 in this chromosome 2-linked pedigree used for MCMC analysis, implying that these individuals may still be too young to display CI onset or may have other protective factors located elsewhere in the genome as the average age of onset for this family is older than the general Amish population. POU3F2 is a known regulator of the nearby gene *Leucine* Rich Repeat Transmembrane neuronal 4 (LRRTM4).[54] The leucine-rich repeat transmembrane proteins (LRRTMs) are primarily expressed in the nervous system where they assist in synaptic differentiation and development.[55,56] Murine *in vivo* studies demonstrated that reduced *LRRTM4* expression led to deficits in excitatory synapse density in dentate gyrus granule cells.[57] Increased expression of LRRTM4 in the hippocampus improves memory in aging rats.[58] Clinically, *LRRTM4* has been associated with Tourette syndrome and autism spectrum disorder, as well as increased risk of suicide attempt in bipolar disorder. [59,60] It is possible that altered transcription in an upstream

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

regulatory region, possibly due to the potential for POU3F2 binding, may play a role in expression differences of *LRRTM4*, which could further contribute to improved cognitive ability in CU patients, as observed in rodent models. In eQTL and PheWAS databases searched, the "T" allele at rs1402906 was associated with increased incidence of autism spectrum disorder as well as lower CTNNA2 expression. Notably, the POU1F1a TF also had perfect consensus binding in the region containing rs1402906 and POU1F1a regulates the CTNNA2 gene[61]. POU1F1a overexpression induces increased expression of *Leucine* Rich Repeat Transmembrane neuronal 1 (LRRTM1),[61] a gene 312 kb away from rs1402906 and within the region of significant linkage on 2p11.2-13.1. *LRRTM1* is highly expressed in the brain and is associated with handedness and schizophrenia in humans.[62] Deletions of this gene lead to hippocampal shrinking, loss of synaptic density, reduced long-term potentiation in hippocampal neurons, and memory deficiencies in mice.[63,64]

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

LRRTM1 resides within the seventh intron of the Catenin Alpha 2 (CTNNA2) gene in an anti-sense orientation, 262kb away from rs1402906. CTNNA2 shares promoters with LRRTM1.[65] These shared promoters induce alternative transcripts of CTNNA2 containing additional 5' exons expressed almost exclusively in the brain. Importantly, these promoters are bi-directional and may regulate both LRRTM1 and the alternative splicing of CTNNA2 as a single functional unit.[66] Exon VIIb of CTNNA2, located on the sense strand corresponding to the *LRRM1* location, is included more frequently in transcription than other alternative exons, especially in the brain. The ratio of expression levels of fulllength CTNNA2 and this isoform may be important for regulating cadherin-dependent adhesion. [66] We note that a previous publication from our group using a subset of our Amish dataset found linkage to dementia in the region surrounding CTNNA2 and suggested it as a potential risk locus for dementia.[32] Here, the "T" allele at rs1402906, linked to cognitive preservation, was an eQTL noted to decrease CTNNA2 expression. CTNNA2 is highly expressed in the brain in both mice and humans.[32,67] It is well categorized in mice, where it

585 regulates function during murine neuronal development, 586 specifically synapse formation and plasticity.[67] 587 Mechanistically, CTNNA2 regulates synaptic spine 588 formation, stabilization, and turnover.[68] CTNNA2 also 589 forms a complex with beta-catenin, which interacts with 590 presenilin, a known contributor to AD pathology. 591 Destabilization of this beta-catenin complex can lead to 592 neuronal apoptosis in mice and humans.[69] The location of 593 potential POU3F2 and POU1F1a binding sites at rs1402906, 594 near HK3me1, HK3me3, and H3K27ac sites indicate 595 predicted enhancer activity nearby a TSS. Thus, POU1F1a binding may initiate transcription of either *LRRTM1*, an 596 597 alternative splicing variant of CTNNA2, or both, as 598 transcription of these genes has been shown to be 599 coregulated, with multiple TSSs for each gene existing within 600 30 bps of each other.[66] Similarly, POU3F2 binding may 601 initiate altered transcription of *LRRTM4*, another gene 602 involved in neurocognition.[58] 603 604 Our analyses highlight the genetic complexity of cognitive 605 preservation in the Amish, with different sub-pedigrees 606 appearing to drive disparate regions of the genome 607 associated with cognitive preservation. Numerous regions

608

609

610

611

612

613

614

615

616

617

618

619 620

621

622

623

624

625

626

627

628

629 630

631

632

633

634 635

636

637

yielded significant or suggestive results, but a region on chromosome 2p11.2-13.1 showed the most robust linkage in an area previously associated with dementia in the Amish, suggesting the possibility of both protective and risk regulatory elements for cognition in this region of the genome. These results lay the foundation for additional studies to identify loci conferring protection against cognitive impairment. **5 REFERENCES** [1] 2021 Alzheimer's disease facts and figures. Alzheimers Dement 2021;17:327-406. https://doi.org/10.1002/ALZ.12328. [2] Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet 2019;51:414–30. https://doi.org/10.1038/s41588-019-0358-2. [3] Williamson J. Goldman J. Marder KS. Genetic Aspects of Alzheimer Disease. Neurologist 2009;15:80. https://doi.org/10.1097/NRL.0B013E318187E76 B. [4] Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics 2013 45:12 2013;45:1452-8. https://doi.org/10.1038/ng.2802.

638 639 640	[5]	Asher S, Priefer R. Alzheimer's disease failed clinical trials. Life Sci 2022;306:120861. https://doi.org/10.1016/J.LFS.2022.120861.
641 642 643 644	[6]	Harper AR, Nayee S, Topol EJ. Protective alleles and modifier variants in human health and disease. Nat Rev Genet 2015;16:689–701. https://doi.org/10.1038/NRG4017.
645 646 647 648 649	[7]	Strauss KA, Puffenberger EG. Genetics, medicine, and the Plain people. Annu Rev Genomics Hum Genet 2009;10:513–36. https://doi.org/10.1146/ANNUREV-GENOM-082908-150040.
650 651 652 653 654 655	[8]	Crowley WK. OLD ORDER AMISH SETTLEMENT: DIFFUSION AND GROWTH. Annals of the Association of American Geographers 1978;68:249–64. https://doi.org/10.1111/J.1467- 8306.1978.TB01194.X.
656 657 658 659 660 661 662	[9]	Welsh KA, Butters N, Mohs RC, Beekly D, Edland S, Fillenbaum G, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology 1994;44:609–609. https://doi.org/10.1212/WNL.44.4.609.
663 664 665	[10]	Teng E, Chui H. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987;48:314–8.
666 667 668 669 670	[11]	Galvin JE, Roe CM, Morris JC. Evaluation of Cognitive Impairment in Older Adults: Combining Brief Informant and Performance Measures. Arch Neurol 2007;64:718–24. https://doi.org/10.1001/ARCHNEUR.64.5.718.
671 672 673	[12]	Arnett JA, Labovitz SS. Effect of Physical Layout in Performance of the Trail Making Test. vol. 7. 1995.
674 675 676	[13]	Kuzma A, Valladares O, Cweibel R, Greenfest- Allen E, Childress DM, Malamon J, et al. NIAGADS: The NIA Genetics of Alzheimer's

Disease Data Storage Site. Alzheimer's & 677 678 Dementia 2016;12:1200-3. 679 https://doi.org/10.1016/J.JALZ.2016.08.018. [14] Beecham GW, Bis JC, Martin ER, Choi SH, 680 DeStefano AL, Van Duijn CM, et al. The 681 Alzheimer's Disease Sequencing Project: Study 682 design and sample selection. Neurol Genet 683 684 2017;3. 685 https://doi.org/10.1212/NXG.000000000000194 686 687 [15] Osterman MD, Song YE, Adams LD, Laux RA, 688 Caywood LJ, Prough MB, et al. The genetic 689 architecture of Alzheimer disease risk in the 690 Ohio and Indiana Amish. Human Genetics and 691 Genomics Advances 2022:3:100114. 692 https://doi.org/10.1016/J.XHGG.2022.100114. 693 [16] Agarwala R, Biesecker LG, Schäffer AA. Anabaptist genealogy database. American 694 695 Journal of Medical Genetics - Seminars in Medical Genetics 2003:121 C:32-7. 696 697 https://doi.org/10.1002/ajmg.c.20004. [17] Garbe JR, Da Y. A software tool for the 698 699 graphical visualization of large and complex 700 populations. Yi Chuan Xue Bao 2003;30:1193-701 5. [18] Liu F, Kirichenko A, Axenovich TI, Van Duijn 702 CM, Aulchenko YS. An approach for cutting 703 704 large and complex pedigrees for linkage 705 analysis. European Journal of Human Genetics 706 2008:16:854-60. 707 https://doi.org/10.1038/ejhg.2008.24. 708 [19] Gogarten SM, Sofer T, Chen H, Yu C, Brody JA, 709 Thornton TA, et al. Genetic association testing 710 using the GENESIS R/Bioconductor package 711 n.d. 712 https://doi.org/10.1093/bioinformatics/btz567. 713 [20] Conomos MP, Reiner AP, Weir BS, Thornton 714 TA. Model-free Estimation of Recent Genetic

Relatedness. Am J Hum Genet 2016;98:127. 715 716 https://doi.org/10.1016/J.AJHG.2015.11.022. 717 [21] Gao X, Becker LC, Becker DM, Starmer JD, 718 Province MA. Brief Report Avoiding the High Bonferroni Penalty in Genome-Wide Association 719 720 Studies. Genet Epidemiol 2010;34:100–5. 721 https://doi.org/10.1002/gepi.20430. 722 [22] Gao X, Starmer J, Martin ER. A Multiple Testing 723 Correction Method for Genetic Association Studies Using Correlated Single Nucleotide 724 725 Polymorphisms. Genet Epidemiol 2008;32:361-726 9. https://doi.org/10.1002/gepi.20310. [23] Gao X. Multiple Testing Corrections for Imputed 727 728 SNPs. Genet Epidemiol 2011;35:154–8. https://doi.org/10.1002/gepi.20563. 729 [24] Gao F, Chang D, Biddanda A, Ma L, Guo Y, 730 Zhou Z, et al. XWAS: A Software Toolset for 731 732 Genetic Data Analysis and Association Studies 733 of the X Chromosome. Journal of Heredity 2015:666-71. 734 https://doi.org/10.1093/jhered/esv059. 735 [25] Abecasis GR, Cherny SS, Cookson WO, Cardon 736 737 LR. Merlin-rapid analysis of dense genetic maps 738 using sparse gene flow trees 2002. https://doi.org/10.1038/ng786. 739 [26] Boyles AL, Scott WK, Martin ER, Schmidt S, Li 740 YJ, Ashley-Koch A, et al. Linkage disequilibrium 741 742 inflates type I error rates in multipoint linkage 743 analysis when parental genotypes are missing. Hum Hered 2005;59:220-7. 744 https://doi.org/10.1159/000087122. 745 [27] Ott J, Wang J, Leal SM. Genetic linkage analysis 746 747 in the age of whole-genome seguencing. Nat 748 Rev Genet 2015;16:275. https://doi.org/10.1038/NRG3908. 749 [28] MERLIN Quick Reference n.d. 750 https://csg.sph.umich.edu/abecasis/Merlin/refere 751 nce.html (accessed November 1, 2023). 752

753 [29] Wijsman EM, Rothstein JH, Thompson EA. 754 Multipoint Linkage Analysis with Many 755 Multiallelic or Dense Diallelic Markers: Markov 756 Chain-Monte Carlo Provides Practical 757 Approaches for Genome Scans on General 758 Pedigrees. Am J Hum Genet 2006;79:846. 759 https://doi.org/10.1086/508472. 760 [30] Tong L, Thompson E. Multilocus lod scores in 761 large pedigrees: combination of exact and 762 approximate calculations. Hum Hered 2008;65:142-53. 763 764 https://doi.org/10.1159/000109731. 765 [31] Halldorsson B V., Palsson G, Stefansson OA, 766 Jonsson H, Hardarson MT, Eggertsson HP, et 767 al. Characterizing mutagenic effects of recombination through a sequence-level genetic 768 769 map. Science 2019;363. https://doi.org/10.1126/SCIENCE.AAU1043. 770 [32] Cummings AC, Jiang L, Velez Edwards DR, 771 Mccauley JL, Laux R, Mcfarland LL, et al. 772 773 Genome-wide association and linkage study in 774 the Amish detects a novel candidate late-onset Alzheimer disease gene. Ann Hum Genet 775 2012;76:342-51. https://doi.org/10.1111/J.1469-776 777 1809.2012.00721.X. 778 [33] Phan L, Jin Y, Zhang H, Qiang W, Shekhtman E, Shao D, et al. ALFA: Allele Frequency 779 Aggregator, National Center for Biotechnology 780 Information, US National Library of Medicine 781 2020. www.ncbi.nlm.nih.gov/snp/docs/gsr/alfa/ 782 783 (accessed July 3, 2023). [34] Rao SSP, Huntley MH, Durand NC, Stamenova 784 EK, Bochkov ID, Robinson JT, et al. A 3D map 785 786 of the human genome at kilobase resolution reveals principles of chromatin looping. Cell 787 2014;159:1665-80. 788 789 https://doi.org/10.1016/j.cell.2014.11.021. [35] Mountjoy E, Schmidt EM, Carmona M. 790 Schwartzentruber J, Peat G, Miranda A, et al. An 791 792 open approach to systematically prioritize causal

variants and genes at all published human 793 794 GWAS trait-associated loci. Nat Genet 795 2021;53:1527–33. https://doi.org/10.1038/S41588-021-00945-5. 796 [36] Ghoussaini M, Mountjoy E, Carmona M, Peat G, 797 798 Schmidt EM, Hercules A, et al. Open Targets 799 Genetics: systematic identification of trait-800 associated genes using large-scale genetics and 801 functional genomics. Nucleic Acids Res 802 2021:49:D1311-20. 803 https://doi.org/10.1093/NAR/GKAA840. 804 [37] Dreos R, Ambrosini G, Groux R, Perier RC, 805 Bucher P. The eukaryotic promoter database in 806 its 30th year: focus on non-vertebrate 807 organisms. Nucleic Acids Res 2017;45:D51-5. 808 https://doi.org/10.1093/NAR/GKW1069. 809 [38] Messeguer X, Escudero R, Farré D, Núñez O, 810 Martínez J, Albà MM. PROMO: detection of 811 known transcription regulatory elements using 812 species-tailored searches. Bioinformatics 813 2002;18:333-4. 814 https://doi.org/10.1093/BIOINFORMATICS/18.2. 815 333. 816 [39] Farré D, Roset R, Huerta M, Adsuara JE, 817 Roselló L, Albà MM, et al. Identification of patterns in biological sequences at the ALGGEN 818 819 server: PROMO and MALGEN. Nucleic Acids Res 2003;31:3651. 820 https://doi.org/10.1093/NAR/GKG605. 821 [40] Noguchi S, Arakawa T, Fukuda S, Furuno M, 822 823 Hasegawa A, Hori F, et al. FANTOM5 CAGE 824 profiles of human and mouse samples. Scientific Data 2017 4:1 2017;4:1-10. 825 826 https://doi.org/10.1038/sdata.2017.112. [41] Ison J. Rapacki K. Ménager H. Kalaš M. Rydza 827 828 E, Chmura P, et al. Tools and data services 829 registry: a community effort to document bioinformatics resources. Nucleic Acids Res 830 2016;44:D38-47. 831 832 https://doi.org/10.1093/NAR/GKV1116.

[42] Barski A, Cuddapah S, Cui K, Roh TY, Schones 833 DE, Wang Z, et al. High-resolution profiling of 834 835 histone methylations in the human genome. Cell 2007;129:823–37. 836 https://doi.org/10.1016/J.CELL.2007.05.009. 837 [43] Sayers EW, Bolton EE, Brister JR, Canese K, 838 Chan J, Comeau DC, et al. Database resources 839 840 of the national center for biotechnology 841 information. Nucleic Acids Res 2022;50:D20–6. 842 https://doi.org/10.1093/NAR/GKAB1112. 843 [44] Arenaza-Urquijo EM, Vemuri P. Resistance vs. 844 resilience to Alzheimer disease: Clarifying terminology for preclinical studies. Neurology 845 846 2018;90:695. 847 https://doi.org/10.1212/WNL.0000000000005303 848 849 [45] Kero M, Paetau A, Polvikoski T, Tanskanen M, 850 Sulkava R, Jansson L, et al. Amyloid precursor 851 protein (APP) A673T mutation in the elderly 852 Finnish population. Neurobiol Aging 853 2013;34:1518.e1-1518.e3. https://doi.org/10.1016/J.NEUROBIOLAGING.20 854 12.09.017. 855 856 [46] Locke PA, Conneally PM, Tanzi RE, Gusella JF, 857 Haines JL. Apolipoprotein E4 allele and 858 Alzheimer disease: examination of allelic 859 association and effect on age at onset in both 860 early- and late-onset cases. Genet Epidemiol 861 1995;12:83–92. 862 https://doi.org/10.1002/GEPI.1370120108. 863 [47] Sims R, Van Der Lee SJ, Naj AC, Bellenguez C, 864 Badarinarayan N, Jakobsdottir J, et al. Rare coding variants in PLCG2, ABI3, and TREM2 865 implicate microglial-mediated innate immunity in 866 867 Alzheimer's disease. Nature Genetics 2017 49:9 2017:49:1373-84. 868 https://doi.org/10.1038/ng.3916. 869 [48] Jiao B, Liu X, Zhou L, Wang MH, Zhou Y, Xiao 870 T, et al. Polygenic Analysis of Late-Onset 871 Alzheimer's Disease from Mainland China, PLoS 872

One 2015;10:e0144898. 873 874 https://doi.org/10.1371/JOURNAL.PONE.014489 875 8. Wang F, Jia J. Polymorphisms of cholesterol 876 metabolism genes CYP46 and ABCA1 and the 877 878 risk of sporadic Alzheimer's disease in Chinese. Brain Res 2007;1147:34-8. 879 880 https://doi.org/10.1016/J.BRAINRES.2007.02.00 5. 881 [50] Ridge PG, Karch CM, Hsu S, Arano I, Teerlink 882 883 CC, Ebbert MTW, et al. Linkage, whole genome 884 sequence, and biological data implicate variants 885 in RAB10 in Alzheimer's disease resilience. 886 Genome Med 2017;9:1-14. 887 https://doi.org/10.1186/S13073-017-0486-888 1/TABLES/4. 889 [51] Chou CT, Liao YC, Lee WJ, Wang SJ, Fuh JL. 890 SORL1 gene, plasma biomarkers, and the risk of 891 Alzheimer's disease for the Han Chinese 892 population in Taiwan. Alzheimers Res Ther 2016;8:1-9. https://doi.org/10.1186/S13195-016-893 894 0222-X/TABLES/4. 895 [52] Santos-Rebouças CB, Gonçalves AP, dos 896 Santos JM, Abdala BB, Motta LB, Laks J, et al. 897 rs3851179 Polymorphism at 5' to the PICALM 898 Gene is Associated with Alzheimer and Parkinson Diseases in Brazilian Population. 899 Neuromolecular Med 2017;19:293-9. 900 https://doi.org/10.1007/S12017-017-8444-901 902 Z/TABLES/2. 903 [53] Beydoun MA, Weiss J, Beydoun HA, Hossain S, Maldonado AI, Shen B, et al. Race, APOE 904 genotypes, and cognitive decline among middle-905 906 aged urban adults. Alzheimers Res Ther 2021;13:1-16. https://doi.org/10.1186/S13195-907 021-00855-Y/FIGURES/3. 908 [54] 909 Rouillard AD, Gundersen GW, Fernandez NF, Wang Z, Monteiro CD, McDermott MG, et al. 910 911 The harmonizome: a collection of processed 912 datasets gathered to serve and mine

knowledge about genes and proteins. Database 913 914 2016;2016. 915 https://doi.org/10.1093/DATABASE/BAW100. [55] Laurén J, Airaksinen MS, Saarma M, Timmusk 916 917 T. A novel gene family encoding leucine-rich 918 repeat transmembrane proteins differentially expressed in the nervous system. Genomics 919 920 2003;81:411-21. https://doi.org/10.1016/S0888-7543(03)00030-2. 921 Linhoff MW, Laurén J, Cassidy RM, Dobie FA, 922 [56] 923 Takahashi H, Nygaard HB, et al. An unbiased 924 expression screen for synaptogenic proteins 925 identifies the LRRTM protein family as synaptic 926 organizers. Neuron 2009;61:734-49. 927 https://doi.org/10.1016/J.NEURON.2009.01.017. 928 [57] Siddiqui TJ, Tari PK, Connor SA, Zhang P, 929 Dobie FA, She K, et al. An LRRTM4-HSPG 930 complex mediates excitatory synapse 931 development on dentate gyrus granule cells. 932 Neuron 2013;79:680-95. 933 https://doi.org/10.1016/j.neuron.2013.06.029. 934 [58] Flores-Páez LA, Pacheco-Rosado J, Alva-935 Sánchez C, Zamudio SR. Cerebrolysin 936 enhances the expression of the synaptogenic 937 protein LRRTM4 in the hippocampus and 938 improves learning and memory in senescent 939 rats. Behavioural Pharmacology 2020;31:491–9. 940 https://doi.org/10.1097/FBP.0000000000000530. 941 [59] Clarke RA, Eapen V. LRRTM4 Terminal Exon 942 Duplicated in Family with Tourette Syndrome. 943 Autism and ADHD. Genes (Basel) 2022;13. 944 https://doi.org/10.3390/GENES13010066. 945 [60] Willour VL, Seifuddin F, Mahon PB, Jancic D, 946 Pirooznia M, Steele J, et al. A genome-wide 947 association study of attempted suicide. Mol 948 Psychiatry 2012;17:433. 949 https://doi.org/10.1038/MP.2011.4. 950 Herman JP, Jullien N, Guillen S, Enjalbert A, 951 Pellegrini I, Franc JL. Research Resource: A

952 Genome-Wide Study Identifies Potential New 953 Target Genes for POU1F1. Molecular 954 Endocrinology 2012;26:1455–63. https://doi.org/10.1210/ME.2011-1308. 955 [62] Francks C, Maegawa S, Laurén J, Abrahams 956 957 BS, Velayos-Baeza A, Medland SE, et al. 958 LRRTM1 on chromosome 2p12 is a maternally 959 suppressed gene that is associated paternally 960 with handedness and schizophrenia. Mol 961 Psychiatry 2007;12:1129. 962 https://doi.org/10.1038/SJ.MP.4002053. 963 [63] Bhouri M, Morishita W, Temkin P, Goswami D, 964 Kawabe H, Brose N, et al. Deletion of LRRTM1 965 and LRRTM2 in adult mice impairs basal AMPA 966 receptor transmission and LTP in hippocampal 967 CA1 pyramidal neurons. Proc Natl Acad Sci U S 968 A 2018;115:E5382-9. 969 https://doi.org/10.1073/PNAS.1803280115. 970 [64] Dhume SH, Connor SA, Mills F, Tari PK, Au-971 Yeung SHM, Karimi B, et al. Distinct but 972 overlapping roles of LRRTM1 and LRRTM2 in 973 developing and mature hippocampal circuits. Elife 2022;11. 974 https://doi.org/10.7554/ELIFE.64742. 975 [65] Kask M, Pruunsild P, Timmusk T. Bidirectional 976 977 transcription from human LRRTM2/CTNNA1 and 978 LRRTM1/CTNNA2 gene loci leads to expression of N-terminally truncated CTNNA1 and CTNNA2 979 isoforms. Biochem Biophys Res Commun 980 2011;411:56-61. 981 982 https://doi.org/10.1016/J.BBRC.2011.06.085. 983 Trinklein ND, Force Aldred S, Hartman SJ, Schroeder DI, Otillar RP, Myers RM. An 984 985 abundance of bidirectional promoters in the 986 human genome. Genome Res 2004;14:62–6. https://doi.org/10.1101/GR.1982804. 987 988 [67] Park C, Falls W, Finger JH, Longo-Guess CM, Ackerman SL. Deletion in Catna2, encoding 989 990 alpha N-catenin, causes cerebellar and 991 hippocampal lamination defects and impaired

startle modulation. Nat Genet 2002;31:279–84. 992 993 https://doi.org/10.1038/NG908. 994 [68] Abe K, Chisaka O, Van Roy F, Takeichi M. 995 Stability of dendritic spines and synaptic contacts is controlled by aN-catenin. Nature 996 997 Neuroscience 2004 7:4 2004;7:357–63. https://doi.org/10.1038/nn1212. 998 [69] Zhang Z, Hartmann H, Do VM, Abramowski D, 999 1000 Sturchler-Pierrat C, Staufenbiel M, et al. Destabilization of beta-catenin by mutations in 1001 1002 presenilin-1 potentiates neuronal apoptosis. 1003 Nature 1998;395:698–702. 1004 https://doi.org/10.1038/27208. 1005 **6 AUTHOR CONTRIBUTIONS** 1006 1007 Jonathan L Haines, William K Scott, and Margaret A 1008 Pericak-Vance helped design the study and obtain funding for this research. Ascertainment of data was 1009 1010 collected and managed by Renee A Laux, Kristy L 1011 Miskimen, M Denise Fuzzell, Sarada L Fuzzell, Sherri D Hochstetler, Laura J Caywood, Jason E Clouse, and 1012 Sharlene D Herington. Cognitive status was 1013 determined by Michael L Cuccaro, Paula K Ogrocki, 1014 1015 Alan J Lerner, and Jeffery M Vance. Yeunjoo E Song, 1016 Leighanne R Main, Michael D Osterman, Audrey Lynn, Daniel A Dorfsman, Larry D Adams, and Michael B 1017 1018 Prough provided data management, organization, and 1019 QC. Analyses were performed by Leighanne R Main,

with assistance from Yeunjoo Song and Michael D. 1020 1021 Osterman. Manuscript writing and drafting was 1022 performed by Jonathan L Haines, Audrey Lynn, and Leighanne R Main. Editing completed by all authors. 1023 1024 7 ACKNOWLEDGMENTS 1025 1026 This research was supported under the National 1027 institutes of Health and National Institute on Aging, 1028 grant AG058066. This research was also supported by an Alzheimer's Disease Translational Data Science 1029 Training Grant, 5T32AG071474-02. 1030 1031 8 CONFLICT OF INTEREST STATEMENT 1032 The authors declare no conflicts of interest. 1033 1034 9 CONSENT STATEMENT 1035 All individuals ascertained in this study supplied written 1036 1037 informed consent under protocols approved by the 1038 IRBs at Case Western Reserve University and the University of Miami. 1039 1040 10 Diversity, Equity, and Inclusion Statement 1041

Our study considers an isolated founder population, not only genetically, but also culturally, as their lifestyles deviate from modern technocratic habits, making the Amish an under-represented population in studies. Additionally, informed consent and community engagement informed our sampling practices and subsequent analyses. We also made efforts to ensure our study cohort consisted of comparable proportions across each sex.

Keywords: Alzheimer disease, cognitive resilience, cognitive resistance, GWAS, linkage, isolated founder population, pedological study

#### FIGURE 1 (Leighanne Main)

Figure 1 – Amish pedigrees. (A) 8,222 individuals 1055 1056 spanning 14 generations are present in this large pedigree. Relationship data was drawn from the AGDB to incorporate 1057 1058 ascertained individuals into existing family trees. Colored 1059 lines are used to connect generations between families. (B) 1060 Example of a 21-bit sub-pedigree generated via PedCut from 1061 the 14-generation pedigree to create computationally tractable units for analyses. An individual's sex was included 1062 during analyses but was removed here for privacy 1063 1064 protection. Black shading indicates individuals who were CU 1065 at their last assessment; clear shading indicates individuals 1066 with CI. Grey shading indicates individuals for whom no 1067 information besides relationship data was available. (C) Larger pedigree connecting chromosome 2-linked smaller 1068 1069 pedigrees. To protect privacy, sex information was included 1070 for analyses but was removed here. Shading indicates the 1071 same phenotypes as in 1B.

### FIGURE 2 (Leighanne Main)

Figure 2 – Genome-wide association study (GWAS) for 1072 **cognitive preservation.** The suggestive association 1073 threshold (p=1x10<sup>-4</sup>) is depicted with a dashed line; the 1074 significant association threshold (p=6.4x10<sup>-7</sup>) was defined 1075 1076 using the simple-M method and is depicted with a solid line. SNPs are represented as dots corresponding to genomic 1077 1078 coordinates within their chromosome (horizontal axis). SNP 1079 density within each chromosome is shown as a heat map 1080 above each chromosome number. Chromosome 23 is the X 1081 chromosome. Eleven loci demonstrated suggestive association, located on chromosomes 1, 3, 5, 6, 7, 11, 13, 1082 1083 14, 15, and 16 (and depicted as pink dots on this figure). No 1084 SNP surpassed the significance threshold for association.

### FIGURE 3 (Leighanne Main)

Figure 3 – Dominant two-point parametric linkage 1085 1086 analysis for cognitive preservation. Dominant linkage analysis on 21-bit pedigrees across all autosomes and the X 1087 1088 chromosome, labeled as chromosome 23. Suggestive (LOD 1089 ≥ 1.86) and significant (LOD ≥ 3.3) thresholds are denoted as the lower and upper dashed horizontal lines, respectively. 1090 1091 A total of 72 significant results were seen across most 1092 chromosomes (excluding chromosomes 14, 16, 22, and 23). 1093 See Supplemental Figure 3 and Supplemental Tables 4 and 1094 4 for the complete list of all loci surpassing significant and 1095 suggestive thresholds.

# FIGURE 4 (Leighanne Main)

1096	Figure 4 - Chromosome 2p11.2-13.1 linkage analysis
1097	results. Two-point dominant (green) and recessive (purple)
1098	linkage results, two-point NPL (blue) and multipoint MCMC
1099	(orange) (significance >3.3, upper dashed line; suggestive
1100	>1.86, lower dashed line).

## FIGURE 5 (Leighanne Main)


Figure 5 – UCSC Genome browser for chromosome 1101 1102 **2p11.2-13.1.** UCSC Genome Browser tracks of protein coding genes in the significant linkage region on 1103 chromosome 2 p11.2-13.1. The observed chromosomal 1104 1105 region is indicated by a red box on the genomic coordinate slider. rs1402906 is located at 79Mb, highlighted by a 1106 1107 vertical red line across the viewer, with 5Mb on either side 1108 shown. This region is located upstream of the genes CTNNA2 and LRRTM1. 1109


## TABLE 1 (Leighanne Main)


Table1 – Loci meeting *ad-hoc* filtering conditions for further investigation. Chromosome number and coordinates are listed for each of the top LOD scores. P-value is listed for suggestive GWAS result near the same location. For 21- and 22-bit pedigree analyses, significant (≥ 3.3) and suggestive (≥ 1.86) HLOD scores are listed, with significant results in bold. Empty cells indicate that no loci surpassed the suggestive or significant threshold for that analysis.


## TABLE 2 (Leighanne Main)


- 1119 Table 2 MCMC linkage analysis for cognitive
- preservation. Chromosome, genomic coordinates, and LOD
- score are depicted in the table. LOD scores in bold surpass











Chr	Location	GWAS	21-bit pedigrees				22-bit pedigrees			
		p-value	I wo-point NPI	and the second s		Multipoint Dominant	Two-point NPL	Two-point Dominant	Two-point Recessive	Multipoint Dominant
1	165,478,920	7.00E-05	1.9		3.4				3.2	
2	78,873,098		2.4	5.9	4.6		1.9	4.9	3	
3	108,251,237	8.20E-05		3.3			2	3.6		
7	139,996,449		2.1	2.4	4.1				3.8	
11	83,081,483		2	4.7	2.9				3.3	
17	4,487,906		·	2.3	·	2.3		4.1		4.1

Chromosome	Location (bp) GRCh38	Top LOD Score		
1	159,476,580 – 167,672,055	1.97		
2	72,972,490 – 80,875,139	4.14		
7	138,047,463 – 141,972,804	0.6		
11	81,074,649 - 85,224,030	2.64		
17	3,492,832 - 5,478,547	0.13		